Medical Properties Trust, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.

Are you a current or former employee of the company?*YesNo

Purchases

+Additional Purchases

Sales

+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:




There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com

In May 2023, MPW, a real estate investment trust specializing in healthcare facilities, announced a recapitalization transaction with Prospect Medical Holdings, involving an equity stake in PHP Holdings, LLC, instead of cash payments. This deal required regulatory approval from California’s Department of Managed Health Care (DMHC). On July 20, 2023, DMHC ordered a hold on the transaction, which MPW did not disclose in its subsequent reports. The Wall Street Journal exposed this on August 18, 2023, causing MPW’s stock to drop significantly. Shareholders then filed a complaint alleging that MPW had made false statements and failed to disclose material information about the transaction’s regulatory status, leading to misleading statements and stock price decline.